Abacavir and Lamivudine Tablets: Dual NRTI Combination Therapy for HIV Infection

Abacavir and Lamivudine Tablets are a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) used in the management of HIV-1 infection. This dual therapy works by inhibiting the reverse transcriptase enzyme, essential for viral replication, effectively lowering the viral load in the bloodstream.

• Abacavir: After intracellular conversion to carbovir triphosphate, it inhibits HIV reverse transcriptase by competing with natural substrates and causing viral DNA chain termination.

• Lamivudine (3TC): Similarly converted intracellularly to 3TC-TP, it incorporates into viral DNA in place of cytidine, causing chain termination and blocking further viral replication.

Together, these agents help:

• Reduce HIV viral load

• Increase CD4 cell counts (immune defense cells)

• Delay disease progression and reduce the risk of opportunistic infections

• Therapeutic Indication

  • Treatment of HIV-1 infection in combination with other antiretroviral agents

  • Recommended for adults and adolescents as part of Highly Active Antiretroviral Therapy (HAART)

  • Used in both initial therapy and in treatment-experienced patients

  • Global Export Reach

    Export destinations include: India, Venezuela, Brazil, Cambodia, Philippines, Nigeria, Myanmar, Thailand, Singapore, Russia, Kyrgyzstan, Tajikistan, Kenya, Zimbabwe, Somalia, Djibouti, Belarus, Macedonian, Turkey